Wu Z, Li ZB, Cai W, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34:1823-1831.
Thonon D, Goblet D, Goukens E, et al. Fully automated preparation and conjugation of N-succinimidyl 4-[18F] fluorobenzoate ([18F] SFB) with RGD peptide using a GE FASTlab synthesizer. Mol Imaging Biol. 2011;13:1088-1095.
Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med. 2005;2:e70.
Zhang X, Xiong Z, Wu Y, et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med. 2006;47:113-121.
Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]galacto-RGD identifies the level of integrin alphavbeta3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alphavbeta3 expression in patients with malignant glioma by [18F] galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861-870.
Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691-698.
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
Ducassou A, Uro-Coste E, Verrelle P, et al. alphavbeta3 integrin and fibroblast growth factor receptor 1 (FGFR1): prognostic factors in a phase I-II clinical trial associating continuous administration of tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. Eur J Cancer. 2013;49:2161-2169.
Schittenhelm J, Schwab EI, Sperveslage J, et al. Longitudinal expression analysis of alphav integrins in human gliomas reveals upregulation of integrin alphavbeta3 as a negative prognostic factor. J Neuropathol Exp Neurol. 2013;72:194-210.
Gayed BA, Youssef RF, Bagrodia A, et al. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int. 2014;113:668-673.
Vogetseder A, Thies S, Ingold B, et al. alphav-integrin isoform expression in primary human tumors and brain metastases. Int J Cancer. 2013;133:2362-2371.
Rabb H, Barroso-Vicens E, Adams R, Pow-Sang J, Ramirez G. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am J Nephrol. 1996;16:402-408.
Mena E, Owenius R, Turkbey B, et al. [18F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing alphavbeta 3 and alpha vbeta 5 integrins. Eur J Nucl Med Mol Imaging. 2014;41:1879-1888.
